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Abstract
Background: Estimates of population-level coverage with prevention of mother-to-child transmission (PMTCT)
services are vital for monitoring programmes but are rarely undertaken. This study describes uptake of PMTCT
services among HIV-positive pregnant women in a community cohort in rural Tanzania.
Methods: Kisesa cohort incorporates demographic and HIV sero-surveillance rounds since 1994. Cohort data were
linked retrospectively to records from four Kisesa clinics with PMTCT services from 2009 (HIV care and treatment
clinic (CTC) available in one facility from 2008; referrals to city hospitals for PMTCT and antiretroviral treatment (ART)
from 2005). The proportion of HIV-positive pregnant women residing in Kisesa in 2005–2012 who accessed PMTCT
service components (based on linkage to facility records) was calculated per HIV-positive pregnancy and by year,
with adjustments made to account for the sensitivity of the linkage algorithm.
Results: Out of 1497 HIV-positive pregnancies overall (to 849 women), 26 % (n = 387/1497) were not linked to any
facility records, 35 % (n = 519/1497) registered for ANC but not HIV services (29 % (n = 434/1497) were not tested at
ANC or diagnosed previously), 8 % (n = 119/1497) enrolled in PMTCT but not CTC services (6 % (n = 95/1497)
received antiretroviral prophylaxis), and 32 % (n = 472/1497) registered for CTC (14 % (n = 204/1497) received ART or
prophylaxis) (raw estimates). Adjusted estimates for coverage with ANC were 92 %, 57 % with HIV care, and 29 %
with antiretroviral drugs in 2005–2012, trending upwards over time.
Conclusions: Population-level coverage with PMTCT services was low overall, with weaknesses throughout the
service continuum, but increased over time. Option B+ should improve coverage with antiretrovirals for PMTCT
through simplified decisions for initiating ART, but will rely on strengthening access to CTC services.
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Background
In 2011, the United Nations Global Plan set out ambi-
tious targets to eliminate mother-to-child transmission
of HIV by 2015 [1]. Scale-up of prevention of mother-to-
child transmission (PMTCT) programmes has contributed
to an estimated reduction of 60 % in new paediatric HIV
infections since 2001, although 240,000 infections still
occurred globally in 2013 [2]. Most infections via mother-
to-child transmission occur in sub-Saharan Africa [2],
with 21 of the 22 Global Plan priority countries, including
Tanzania, located in the region [1]. Estimates suggest 65 %
of HIV-infected pregnant women living in these countries
received antiretroviral (ARV) drugs for PMTCT in 2012,
falling short of targets for universal coverage [3].
PMTCT programmes include a ‘cascade’ of services
beginning with antenatal clinic (ANC) attendance and
provider-initiated HIV testing and counselling (PITC)
(Fig. 1). Pregnant women diagnosed with HIV are
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referred to HIV clinics for long-term care and treatment,
provided antiretroviral drugs, advised to deliver in a
health centre, and counselled about infant feeding. HIV-
exposed infants receive ARV prophylaxis, are tested for
HIV, and if diagnosed HIV-positive are enrolled in HIV
programmes. Global PMTCT guidelines have evolved
from short-course ARV prophylaxis for mothers and in-
fants to prevent HIV transmission, towards longer and
more potent ARV regimens with the potential to im-
prove maternal health [4, 5]. The latest guidelines (‘Op-
tion B+’) recommend all HIV-positive pregnant women
initiate ART for life [4]. Several African countries have
adopted this approach, including Tanzania which began
implementing Option B+ in 2013 [6].
Estimates of coverage with PMTCT services among all
HIV-infected pregnant women are vital to monitor pro-
gress relative to targets, and to secure donor funding for
PMTCT programmes [7]. Measuring coverage for each
component of the cascade can highlight programme
weaknesses where a disproportionately high number of
women fail to receive PMTCT services. However, national-
level PMTCT coverage may be over-estimated due to
problems with the quality of aggregated programme data
(numerator) and estimating or modelling the number of
pregnant HIV-positive women (denominator) [7]. Further-
more, national-level estimates may mask substantial re-
gional differences in coverage, but regional-level estimates
are rarely available. Most research investigating uptake of
PMTCT components starts from the point of programme
entry, missing HIV-infected women who are undiagnosed,
or diagnosed but do not seek services [8]. Innovative ap-
proaches have been attempted by researchers in West and
Southern Africa to measure coverage with PMTCT
prophylaxis (nevirapine) using umbilical cord blood sam-
ples, but these cross-sectional surveillance studies were
also limited to women who attended health services for
delivery [9].
Linkage of community research data to routinely col-
lected clinic data provides an important opportunity to
calculate direct estimates of coverage with PMTCT ser-
vices, yet very few studies have used this approach [7]. A
recent study from a demographic surveillance system
(DSS) site in Malawi determined uptake of PMTCT ser-
vices by linking records of DSS residents to health ser-
vice data, reporting sub-optimal uptake of ART (67 % on
ART during pregnancy or delivery) in the context of Op-
tion B+ [10]. High coverage (96 %) of ANC services, but
only 64 % coverage with HIV testing during pregnancy,
was documented within a population cohort study in
Uganda [11]. No studies have provided direct estimates
of PMTCT service coverage over time since the imple-
mentation of PMTCT programmes at a local level, nor
the coverage at successive steps of the cascade, despite
the value of such data for service monitoring. We, there-
fore, used data from a community cohort study in
north-west Tanzania to describe and measure uptake of
PMTCT services among HIV-positive pregnant women,
including trends over time since the introduction of HIV
and PMTCT services to the area, prior to the implemen-
tation of Option B+.
Methods
Setting
This study took place in Kisesa, a rural community of
approximately 30,000 in north-west Tanzania, 20 km to
the east of Mwanza city in Magu District. Population
HIV prevalence was 6 % in women in 2011 [12] and 8 %
among pregnant women during ANC surveillance across
Magu district in 2006 [13].
Four government-run health facilities in Kisesa offer
PMTCT services (since 2009). The health centre in the
trading centre includes an ANC, voluntary counselling
and testing (VCT) clinic (opened 2005), and HIV care
and treatment clinic (CTC) (opened 2008). Between
2005 and 2008, pregnant women diagnosed HIV-positive
at the VCT clinic were referred to Bugando hospital in
Mwanza city for PMTCT services. Three dispensaries,
located 5–10 km from the health centre in more rural
villages, offer basic PMTCT services including HIV test-
ing at ANC, provision of ARV prophylaxis when stocks
are available, and referral to Kisesa health centre CTC.
From 2008 to 2012, blood samples were transported
Fig. 1 PMTCT cascade of services for mothers and infants. ANC antenatal clinic, ARV antiretroviral, ART antiretroviral therapy, PITC provider initiated
testing and counselling, VCT voluntary counselling and testing. *ARV prophylaxis for PMTCT, or ART for the woman’s own health if she meets
eligibility criteria. **Woman was pregnant at the time of VCT or other PITC, or became pregnant after registration at the HIV clinic, before or after
starting ART
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from Kisesa CTC to Bugando hospital for CD4 count
testing.
From 2005, national guidelines recommended single-
dose nevirapine for mothers during labour and for in-
fants immediately after birth, and from 2007 to 2011,
ARV prophylaxis for HIV-positive pregnant women from
28 weeks gestation, during delivery and post-partum for
7 days, with infant ARV prophylaxis recommended for
≤4 weeks after birth [14] (Table 1). Women with CD4
counts <200 cells/mm3, clinical stage 4, or clinical stage
3 with CD4 <350 were eligible to initiate ART [14]. In
2012, the threshold for ART eligibility was raised to
CD4 <350, and prophylaxis was prescribed from 14 weeks
gestation until 7 days post-partum to mothers and until
cessation of breastfeeding for infants (‘Option A’) [15].
Demographic and HIV sero-surveillance
An open cohort study has been ongoing in Kisesa since
1994, including a DSS with rounds (28 to-date) of
household enumeration every 4–12 months recording
pregnancies, births, deaths, migrations, and 7 rounds of
HIV sero-surveillance at approximately 3 year intervals
(sero-survey7 in 2013). Adults aged ≥15 are eligible to
participate in the sero-surveys. Participants who give
their consent are tested for HIV without disclosure of
results, offered VCT (since 2004), and interviewed about
their use of health services. Detailed methods for the co-
hort were described previously [16, 17].
Clinic data
ANC pregnancy registers for 2005–2012 and PMTCT
programme registers for 2009–2012 were collected
retrospectively from all four Kisesa-based facilities. Less
than 10 % of records were missing. Data were double-
entered into a custom-built database by trained data
entry clerks at the National Institute of Medical Re-
search in Mwanza and stored on a password-restricted
computer network (PMTCT programme registers con-
tain registration numbers: names of HIV-positive pa-
tients are not visible). CTC data are entered into a
national database by government data entry clerks. Data
were abstracted from 2005 to 2012 (names are stored in
encrypted format), including data for Kisesa-resident pa-
tients who initially enrolled at Bugando CTC.
Record linkage
Clinic records were linked to community cohort data
with an automated matching procedure using personal
attributes such as name, sex, age, and pregnancy dates.
The algorithm was developed using a gold standard
based on anonymous identification numbers collected
from women’s ANC cards during DSS round 27. Ap-
proximately 80 % of ANC and CTC clinic records for
women from Kisesa were linked to a DSS record. Posi-
tive predictive value of the algorithm was 98 %, with a
sensitivity of 70 %. CTC records for women of child-
bearing age were matched using a similar algorithm.
Clinic records for the same woman in ANC, PMTCT or
CTC registers were linked using ANC registration num-
bers and/or CTC numbers. Linked datasets were stored
on a secure computer network, and analytical datasets
were stripped of identifying information.
Statistical analysis
Analyses were carried out using Stata12 (Stata Corp LP,
Texas, USA). The denominator included pregnancies to
HIV-positive women in Kisesa, resident in 2005–2012.
HIV-positivity was determined from research testing
during HIV sero-surveys, or linkage of a DSS record to
an HIV-positive clinic record (for women whose HIV
status was not known from sero-survey testing, or who
had sero-converted since last testing HIV-negative). Sero-
conversion dates were estimated, taking the mid-point
between last HIV-negative and first HIV-positive test re-
sults for sero-incident cases. For prevalent cases, sero-
conversion dates were estimated as three years prior to
first testing HIV-positive at a sero-survey (based on data
for sero-incident cases by sex and age). Pregnancies to
HIV-positive women were identified using children’s dates
of birth with links to mothers, mothers’ self-reports of re-
cent births and pregnancies in the DSS and sero-surveys,
or pregnancies recorded in the clinic. Women who were
resident in Kisesa and pregnant in 2005–2012, whilst
HIV-positive, were eligible for inclusion. Women who be-
came HIV-positive after pregnancy were excluded.
Table 1 Summary of PMTCT interventions in Kisesa
Year of implementation Intervention – mother (ARV prophylaxis) CD4 count threshold for ART (cells/mm3) Intervention – infant
2005 Sd-NVP during labour & delivery CD4 <200 Sd-NVP to infants within 72 hours
of birth
2007 AZT from 28 weeks gestation; sd-NVP +
AZT + 3TC during labour; AZT + 3TC
until 7 days postpartum
CD4 <200 NVP for 1 week after birth and AZT
for up to 4 weeks
2012 ‘Option A’: AZT from 14 weeks gestation;
sd-NVP + AZT + 3TC during labour; AZT +
3TC until 7 days postpartum
CD4 <350 NVP until 1 week after cessation of
breastfeeding (or 4–6 weeks if
replacement feeding)
(sd-NVP) single-dose nevirapine; (AZT) azidothymidine; (3TC) lamivudine
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The proportion of women accessing each service, per
pregnancy, was calculated overall and by year of preg-
nancy. Service use was based on linkage of a woman’s
DSS record to a clinic (ANC or CTC) record. Dates of
pregnancy and clinic attendance were aligned to deter-
mine service access during a particular pregnancy. Re-
ceipt of ARV drugs during pregnancy was defined
using PMTCT registers which capture ARVs dispensed
during ANC, or CTC records (continuation of ART at
the time of pregnancy, or initiation of ART before the
recorded or estimated delivery date). PMTCT registers
were also used to abstract data on gestational age at
the time of enrolment into the PMTCT programme.
Diagnosis of HIV before pregnancy or CTC registration
was determined using attendance at VCT services in
sero-surveys, or self-reported VCT use in sero-survey
interviews. Diagnosis at ANC was based on linkage to
HIV test results in PMTCT testing registers, or prior
VCT. The proportions of women enrolling in HIV care
by facility type were calculated among individuals who
registered at ANC services and compared using chi
square tests.
Estimates of coverage with PMTCT services (enrol-
ment in ANC, HIV care, and receipt of ARVs during
pregnancy) were adjusted for cases of clinic attendance
that were missed by the linkage algorithm: raw propor-
tions were divided by the proportion of clinic records
that were linked to the DSS, or by the algorithm sensi-
tivity (Additional file 1). Estimates were also adjusted
by the proportion of women who may have accessed
ANC services outside Kisesa (measured in sero-survey7
as 12 %).
Kaplan-Meier survival plots were used to analyse
time to CTC registration. Time was calculated from
the ANC registration date (or reported pregnancy date
if ANC registration date was unknown) to the CTC
registration date (or date of next visit to the CTC if
already registered), or date of exit from the DSS (out-
migration, death or enumerated in the latest round),
or end of the study period (Dec 31 2012) if this pre-
ceded the DSS exit date. Log-rank tests were used to
compare differences in time to registration by year of
pregnancy.
ANC clinic records that were linked to the DSS by
the matching algorithm (n = 9842 in total, including
HIV-positive and HIV-negative women) were compared
to unlinked ANC clinic records (n = 2579), for women
documented as residing in Kisesa, in order to investi-
gate the potential for bias. Descriptive cross-tabulations
and chi-squared tests were used for this purpose. The
same descriptive analyses were also conducted to com-
pare CTC records (for Kisesa-resident women) that
were linked (n = 661), versus not linked (n = 174), to
DSS records.
Ethical approval
This study was granted ethical approval by the London
School of Hygiene and Tropical Medicine, and the Tan-
zanian Medical Research Coordinating Committee.
Results
Eight hundred and forty eight Kisesa-resident women
had ever tested HIV-positive during sero-surveillance.
Another 618 DSS records were newly identified as HIV-
positive based on their linkage to a record in PMTCT
registers or the CTC. Of these women, 849 had been
pregnant in 2005–2012 since they were infected, giving a
denominator of 1497 pregnancies while HIV-positive
(49 % out of 849 women had ≥2 pregnancies) (Fig. 2).
Characteristics of the study population
Table 2 presents characteristics of included women
around the time of pregnancy. Half the women were
aged between 20 and 29 while pregnant, 72 % were mar-
ried, 40 % were residing in remote rural villages (31 % in
the trading centre, 29 % in roadside villages), and 67 %
Fig. 2 Flow chart of participants eligible for inclusion in the analysis
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were in their third or later pregnancy (median 3rd
pregnancy).
Uptake of PMTCT services
Figure 3 illustrates raw estimates for uptake of PMTCT
service components overall, and by year of pregnancy.
Of the 1497 pregnancies to (849) HIV-positive women
overall, 387 (26 % out of 1497) were not linked to ANC
or HIV services during their pregnancy, of whom 82
(21 % out of 387) were already diagnosed (had VCT dur-
ing earlier sero-surveys). Thirty-five percent (n = 519/
1497) registered at ANC but did not enrol in HIV ser-
vices, of whom 434 (84 % out of 519; 29 % overall) had
not had an HIV test at ANC or earlier VCT. A small
proportion (8 %, n = 119/1497) enrolled in the PMTCT
programme at ANC but not at the CTC: most (80 % out
of 119; 6 % overall) had received ARV prophylaxis. HIV-
positive women who enrolled in the PMTCT programme
in 2012 had a median gestational age of 24 weeks (IQR
20–28).
Thirty-two percent (n = 472/1497) had registered at
the CTC, of whom 204 (43 % out of 472; 14 % overall)
had received ART or ARV prophylaxis during preg-
nancy. Overall, 20 % out of 1497 accessed ARV drugs
during pregnancy at ANC or CTC. Ninety-seven (21 %
out of 472, or 6 % overall) had already started ART
(there were very few documented treatment interrup-
tions, although 3 had not been seen for over 12 months,
and 12 transferred to another clinic). Among 268 who
registered at the CTC but did not acquire ARVs, 45
(17 % out of 268) had not attended CTC appointments
for >12 months. Among those who had not started ART
(n = 319), 48 % had no CD4 result recorded, while 11 %
were eligible for ART.
Prior to 2008, few individuals were enrolled in HIV
services during pregnancy. Uptake of PMTCT services
increased over time, with the largest increases occurring
between 2007 and 2008 (opening of Kisesa CTC) and
between 2008 and 2009 (implementation of the PMTCT
programme in Kisesa). In 2009, 44 % (n = 85/192) had
enrolled in the CTC or ANC-based PMTCT services,
and 17 % (n = 32/192) had been prescribed ARV prophy-
laxis or ART. These proportions increased to 68 % (n =
184/269) in care and 44 % (n = 117/269) accessing ARVs
in 2012 (raw estimates). Among those registered at the
CTC in 2012 (n = 134), 39 (29 %, or 14 % out of 269)
had already started ART. Eighteen women eligible for
ART in 2012 had not started (23 % out of 78 CTC pa-
tients not on ART, versus 9 % in 2009).
Women who attended ANC at dispensaries (n = 389
pregnancies) were less likely to be in care (n = 148, 38 %)
Table 2 Characteristics of HIV-positive women in Kisesa at the
time of/closest to each pregnancy (N = 1497 pregnancies)
Factor Category Number of
pregnancies
% of
pregnancies
Age <20 88 5.9
20–29 749 50.0
30–39 576 38.5
40+ 84 5.6
Year of pregnancy 2005 74 4.9
2006 135 9.0
2007 159 10.6
2008 199 13.3
2009 192 12.8
2010 220 14.7
2011 249 16.6
2012 269 18.0
Residence area Remote rural 600 40.1
Roadside 434 29.0
Trading Centre 463 30.9
Marital status Currently married 1079 72.1
Never married 150 10.0
Previously married 267 17.9
Graviditya 1 217 14.5
2 275 18.4
3 305 20.4
4 238 15.9
5+ 462 30.9
a49 % of 849 women contributed ≥2 pregnancies to this analysis
Fig. 3 Raw proportions of pregnancies to HIV-positive women in
Kisesa in which PMTCT services were accessed. ANC antenatal clinic,
ARV antiretroviral, ART antiretroviral therapy, CTC (HIV) care and
treatment clinic, PMTCT prevention of mother-to-child transmission.
"Diagnosed" [not registered at ANC, PMTCT, or CTC] refers to women
who were aware of their HIV status through VCT during earlier sero-
surveys. "Diagnosed" [registered at ANC only] refers to women who
were aware of their HIV status through earlier VCT during sero-
surveys, or provider-initiated HIV testing and counselling at ANC
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than women who attended ANC at the health centre
(51 % out of 569 pregnancies) (p <0.001), with the differ-
ential remaining over time (Fig. 4).
Coverage estimates
Adjusted coverage estimates for the proportion of HIV-
positive women who accessed ANC, PMTCT/CTC (HIV
care), and ARVs per pregnancy in 2005–2012 are sum-
marised in Table 3. The (adjusted) proportion of HIV-
positive women accessing ANC was estimated to be as
high as 92 %, 57 % for access to HIV care, and 29 % for
coverage with ARV drugs. By 2012, coverage with HIV
care was estimated to reach >90 % while coverage with
ARVs reached 62 % (calculations in Additional file 1).
Time to CTC visit
Figure 5 illustrates the time to CTC visit by calendar
year of pregnancy over the first six months of follow-up.
Time to CTC visit decreased with increasing year of
pregnancy (p <0.001). For pregnancies since 2009 a
steeper increase was noticeable within the first month
compared to earlier years, corresponding to a greater
proportion of women visiting the CTC within this time
window.
Characteristics of clinic attendees by linkage to the DSS
Compared to ANC records that were linked to the DSS
(n = 9842), unlinked (Kisesa-resident) ANC records (n =
2579) were more often from a dispensary (44 % versus
39 %, p <0.001) (data not shown), but there was no dif-
ference in age or year of registration. A greater proportion
of unlinked CTC records (n = 174) were registrations prior
to 2008 (25 %, compared to 3 % of linked CTC records (n
= 661), p <0.001), but there was no difference in age,
village of residence, clinical stage or CD4 count at
registration.
Discussion
This study documented fairly low population-level up-
take of PMTCT services in rural Tanzania in 2005–2012
before the implementation of Option B+. However, pri-
mary care ART and PMTCT services were only intro-
duced in Kisesa in 2008–9, after which there was an
encouraging upward trend in service use over time;
coverage with HIV care during pregnancy rose to 68 %
(raw; >90 % adjusted), and with ARV drugs to 44 %
(raw; 62 % adjusted) in 2012. These estimates are lower
than national-level estimates of coverage with ARVs for
HIV-positive pregnant women in Tanzania (73 % in
2013 [2]), potentially reflecting over-estimates at the na-
tional and regional levels [7], and/or local level differ-
ences. ANC surveillance across Magu District in 2008
identified very low usage of ARVs (33 %) for PMTCT
based on self-reports by pregnant women [18]. Qualita-
tive research in Kisesa and other African studies have
identified many factors at the level of individuals (e.g.,
psychological issues following diagnosis, and poor know-
ledge of HIV), the community (e.g., stigma, fear of dis-
closing HIV status, and the amount of support from
partners or relatives) and health-systems (e.g., accessibil-
ity of services, staff shortages, and interactions between
patients and health care providers) that may contribute
to poor uptake of PMTCT services [19, 20]. A quantita-
tive analysis also revealed that marital status (currently
married), increasing age, residence in roadside areas,
later calendar time period (year of pregnancy) and in-
creasing infection duration were associated with greater
access to HIV care and/or ARV drugs for PMTCT in
Kisesa [21].
Weaknesses in the PMTCT programme were evident
throughout the cascade, but were notable at the point of
testing, assessment for ART eligibility and receipt of
ART or prophylaxis. The adjusted estimate for coverage
Fig. 4 Access to HIV care, per pregnancy, among HIV-positive women enrolled in Kisesa ANC (health centre/dispensaries). ANC antenatal clinic,
CTC care and treatment clinic, PMTCT prevention of mother-to-child transmission
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with ANC was within the range of survey data for
Mwanza region in 2010 (86 %) [22] and Kisesa (98 % in
2010 (sero-survey6); 90 % in 2013 (sero-survey7)). Our
analysis also identified some HIV-positive women who
were aware of their status through earlier VCT but did
not attend health services during pregnancy, calling for
strengthened post-test counselling about the importance
of PMTCT.
The sizeable proportion of HIV-positive women who
were not enrolled in PMTCT or CTC services during
pregnancy was primarily accounted for by women who
attended ANC but were not diagnosed (were not tested
at ANC and did not have earlier VCT). This is most
likely explained by frequent and persistent stock-outs of
HIV test kits during the study time-frame [19, 23]. Low
coverage (64 %) with HIV testing at ANC was also docu-
mented in Uganda in 2008–2010 [11], while Tanzanian
programme statistics indicate that 20 % of women at-
tending ANC were not tested in 2011 [24]. Some women
may decline testing, fearing disclosure of HIV-positive
results and consequent conflict in relationships [19, 25].
Improvements in the distribution of HIV test kits,
community-level interventions to reduce HIV stigma, as
well as adequate pre-test counselling (sometimes omit-
ted [23]) may help to reduce drop-outs at this stage.
Most women who enrolled in the PMTCT programme
received ARV prophylaxis and were therefore covered
with the minimum PMTCT intervention. However, this
pre-supposes (for maximum efficacy) optimal adherence
and initiation of ARVs from the recommended gesta-
tional age, while further analyses of PMTCT clinic re-
cords revealed that women were registering late (median
24 weeks (IQR 20–28) in 2012). As Tanzania rolls out
Option B+, it will be important to emphasise the import-
ance of attending ANC early, and to monitor the sub-
group that registers for PMTCT but not CTC or ART
services. Research from Malawi indicates that some
pregnant women may avoid ART, for example because
they feel in good health [10]. Other reasons for not tak-
ing up ART in the context of Option B+ may include
anxiety about the prospect of taking treatment for life,
feeling overwhelmed, as well as more general barriers to
ART including facility accessibility, stigma, fear of dis-
closure, and limited knowledge of ART [26].
Access to CTC services, including the time to CTC at-
tendance, improved each year following the availability
of ART and PMTCT services in Kisesa, but remained a
point of further attrition. Linkage to HIV care and treat-
ment has been highlighted as a problematic step in the
PMTCT programme [27], including in Mwanza city
[28]. Starting ANC at dispensaries was apparently a dis-
advantage, reflecting the need for referrals to the CTC
and associated accessibility issues [19]. Further decen-
tralisation of ART services would help in this regard and
will be crucial to the success of Option B+. Improve-
ments in the design, usage and storage of PMTCT trans-
fer forms may also strengthen linkages between ANC
and CTC [29].
A considerable weakness was the uptake of ARV drugs
among those registered for CTC. Almost a quarter of
women eligible for ART in 2012 had not received it, po-
tentially reflecting adjustment to new (widened) eligibil-
ity criteria. Losses to follow-up were also partly
responsible for not initiating treatment, while half the
Table 3 Coverage estimates (raw/adjusted) for the proportion of HIV-positive women accessing service components per pregnancy
(2005–2012)
Service Raw estimate Estimate adjusted by % ANC
records linked to DSS*
Estimate adjusted by % ANC records
linked to DSS & local ANC attendance**
Estimate adjusted by
algorithm sensitivity***
ANC 64.0 %a [61.6–66.4 %] 80.6 % 91.6 % 91.4 %
In HIV care (PMTCT/CTC) 39.5 % [37.0–42.0 %] 49.7 % 56.5 % 56.4 %
ARV drugs 20.0 % [17.9–22.0 %] 25.2 % 28.6 % 28.6 %
ANC antenatal clinic, ARV antiretroviral, CTC care and treatment clinic, DSS demographic surveillance system, PMTCT prevention of mother-to-child transmission
*raw estimate divided by 79 % (% of ANC records linked to the DSS)
**previous estimate (column three) divided by 88 % (accounting for 12 % of women that reported accessing ANC services outside Kisesa ward in sero7)
***divided by 70 % (sensitivity of the algorithm)
a raw estimate for the proportion who attended ANC, excluding women who attended CTC in Kisesa but were not linked to Kisesa ANC services (e.g., may have
attended ANC outside the area)
Fig. 5 Kaplan Meier plot of time to CTC visit by year of pregnancy
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women who had not started ART had no CD4 count
documented. Limited CD4 count testing was also re-
ported in PMTCT programmes in Mwanza city hospitals
[28]. Implementation of Option B+ will simplify decisions
regarding ART initiation for HIV-positive pregnant women
by eliminating the need to assess treatment eligibility
through CD4 counts. Point of care CD4 count tests have
recently been introduced and should improve long-term
monitoring of immunological status. Nonetheless, women
without CD4 counts or ineligible for ART should have re-
ceived ARV prophylaxis. Documentation of prophylaxis in
the CTC database was weak, with additional hand-written
notes non-systematically present in patient files. The pro-
portion receiving prophylaxis may therefore be under-esti-
mated, highlighting the importance of robust and
systematic approaches to routine data capture [7].
The increasing proportion of women who were already
on ART before pregnancy (14 % in 2012) is noteworthy,
as this population presents new challenges for PMTCT
programmes, including monitoring of treatment adher-
ence and virologic suppression [30], and will grow with
Option B+.
Linkage of community cohort and clinic data was the key
strength and novelty of this analysis, providing estimates of
population-level coverage with PMTCT services, although
there were inherent limitations. The proportion of clinic
records that was not linked to the DSS was accounted for,
but was a potential source of bias given differences ob-
served in the characteristics of linked and unlinked clinic
records: uptake of services before 2008 or in the dispensar-
ies may be under-estimated, although this is unlikely to
have altered our conclusions. Routine clinic data were ab-
stracted retrospectively from health facility registers, con-
tributing to general limitations in the data quality. Poor
quality of some clinic data (e.g., missing or duplicate identi-
fiers) complicated the linkage of records from different reg-
isters and tracking of women who had switched facilities
[7], potentially under-estimating the proportions tested and
enrolled in care, although mis-matches are likely to have
resulted in random misclassification of outcomes. The
large proportion (approximately 20 %) of delivery registers
missing ANC numbers and difficulties linking infant and
maternal records also restricted our analysis to PMTCT
service components during pregnancy. Weaknesses in fa-
cility record-keeping may have partly explained low cover-
age of ARV prophylaxis. Estimated HIV sero-conversion
dates or self-reported pregnancy dates may be inaccurate,
and HIV-positive pregnancies may have been erroneously
included in or omitted from the denominator, leading to
under- or over-estimates of coverage respectively.
Conclusion
In conclusion, population-level uptake of PMTCT ser-
vices in this rural Tanzanian setting was disappointingly
low and below national-level estimates, but improved
markedly over time. Given the proportion of women
who fully adhere to regimens and the proportion of
mothers and infants receiving ARVs is likely to be even
lower, the number of infants potentially at risk of acquir-
ing HIV is a concern. Implementation of Option B+ is
likely to simplify decisions for initiating HIV-positive
pregnant women onto ART, while further decentralisa-
tion of CTC services and careful management of stocks
of HIV test kits will be key to overcoming other weak-
nesses in the PMTCT programme.
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